See more : Capitalworks Emerging Markets Acquisition Corp (CMCAF) Income Statement Analysis – Financial Results
Complete financial analysis of Rafarma Pharmaceuticals, Inc. (RAFA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rafarma Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Burnham Holdings, Inc. (BURCB) Income Statement Analysis – Financial Results
- Orion Oyj (ORINF) Income Statement Analysis – Financial Results
- Bengal Tea & Fabrics Limited (BENGALT.BO) Income Statement Analysis – Financial Results
- Koa Shoji Holdings Co.,Ltd. (9273.T) Income Statement Analysis – Financial Results
- Frontline Corporation Limited (FRONTCORP.BO) Income Statement Analysis – Financial Results
Rafarma Pharmaceuticals, Inc. (RAFA)
About Rafarma Pharmaceuticals, Inc.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 10.14M | 64.31M | 77.41M | 74.73M | 11.44M | 147.20K | 125.10K | 0.00 | 0.00 |
Cost of Revenue | 9.54M | 41.50M | 50.14M | 41.65M | 8.09M | 143.59K | 195.94K | 0.00 | 0.00 |
Gross Profit | 600.00K | 22.81M | 27.27M | 33.08M | 3.36M | 3.61K | -70.84K | 0.00 | 0.00 |
Gross Profit Ratio | 5.92% | 35.47% | 35.23% | 44.27% | 29.32% | 2.45% | -56.63% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 150.00K | 5.42M | 5.36M | 8.10M | 0.00 | 9.20K | 26.23K | 1.00K | 0.00 |
Other Expenses | 137.00K | -10.25M | -7.19M | -5.90M | -262.09K | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 287.00K | 15.66M | 12.55M | 14.00M | 262.09K | 9.20K | 26.23K | 1.00K | 0.00 |
Cost & Expenses | 9.82M | 57.16M | 62.69M | 55.65M | 8.35M | 152.79K | 222.17K | 1.00K | 0.00 |
Interest Income | 0.00 | 599.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 7.00K | 39.38K | 595.00 | 0.00 | 13.85K | 0.00 |
Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 466.00K | 161.14K | 52.52K | 0.00 | 0.00 |
EBITDA | 313.00K | 6.23M | 14.73M | 19.08M | 3.56M | -5.58K | -97.07K | -1.00K | 0.00 |
EBITDA Ratio | 3.09% | 11.12% | 19.02% | 25.54% | 31.11% | -3.79% | -77.60% | 0.00% | 0.00% |
Operating Income | 313.00K | 7.15M | 14.73M | 19.08M | 3.09M | -5.58K | -97.07K | -1.00K | 0.00 |
Operating Income Ratio | 3.09% | 11.12% | 19.02% | 25.53% | 27.03% | -3.79% | -77.60% | 0.00% | 0.00% |
Total Other Income/Expenses | 47.00K | -925.00K | -138.00K | -519.00K | -39.38K | -599.00 | 0.00 | -13.85K | 0.00 |
Income Before Tax | 360.00K | 6.23M | 14.59M | 18.56M | 3.05M | -6.18K | -97.07K | -14.85K | 0.00 |
Income Before Tax Ratio | 3.55% | 9.68% | 18.84% | 24.84% | 26.69% | -4.20% | -77.59% | 0.00% | 0.00% |
Income Tax Expense | 87.00K | 1.26M | 3.01M | 3.72M | 0.00 | 4.00 | -52.52K | 0.00 | 0.00 |
Net Income | 273.00K | 4.96M | 11.57M | 14.85M | 3.05M | -6.18K | -97.07K | -14.85K | 0.00 |
Net Income Ratio | 2.69% | 7.71% | 14.95% | 19.87% | 26.69% | -4.20% | -77.59% | 0.00% | 0.00% |
EPS | 0.00 | 0.06 | 0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | 0.00 | 0.06 | 0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 87.77M | 87.77M | 87.77M | 87.77M | 93.17M | 83.87M | 83.87M | 82.87M | 77.67M |
Weighted Avg Shares Out (Dil) | 87.77M | 87.77M | 87.77M | 87.77M | 93.17M | 83.87M | 83.87M | 82.87M | 77.67M |
Rafarma Embarks on Aggressive Global Partnerships Plan
Source: https://incomestatements.info
Category: Stock Reports